Lilly’s Verzenio misses key survival goal in lung cancer

11th October 2017 Uncategorised 0

Eli Lilly’s breast cancer drug Verzenio has failed to improve overall survival in a late-stage study assessing the drug’s potential in patients with KRAS-mutated, advanced non-small lung cancer (NSCLC).

More: Lilly’s Verzenio misses key survival goal in lung cancer
Source: News